,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,13,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
6,15,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
7,19,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
8,21,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
9,23,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
10,25,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
11,29,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
12,33,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
13,35,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
14,37,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
15,39,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
16,41,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
17,43,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
18,45,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
19,47,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
20,49,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
21,53,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
22,55,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
23,59,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
24,65,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
25,67,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
26,71,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
27,73,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
28,77,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
29,79,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
30,81,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
31,83,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
32,85,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
33,87,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
34,91,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
35,93,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
36,95,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
37,97,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
38,99,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
39,101,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
40,105,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
41,107,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
42,109,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
43,113,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
44,115,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
45,119,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
46,121,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
47,123,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
48,125,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
49,131,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
50,137,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
51,139,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
52,141,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
53,143,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
54,145,1,1,,69416,445858,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
55,155,1,1,,69416,445858,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
56,157,1,1,,69416,445858,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
57,161,1,1,,69416,445858,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
58,165,1,1,,69416,445858,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
59,167,1,1,,69416,445858,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
60,175,1,1,,69416,445858,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
61,608,1,6,,11537687,445858,Inactive,17149836.0,2280.0,,,NMR Based Screening Assay for FKBP12,Other,,
62,875,1,2,,26748470,445858,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
63,880,2,1,,26748470,445858,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
64,880,2,1,,26748470,445858,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
65,881,2,2,,26748470,445858,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
66,884,1,2,,26748470,445858,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
67,885,1,2,,26748470,445858,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
68,887,1,2,,26748470,445858,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
69,889,1,3,,26748470,445858,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
70,892,1,2,,26748470,445858,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
71,893,1,2,,26748470,445858,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
72,893,1,2,,26748470,445858,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
73,894,2,1,,26748470,445858,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
74,900,1,3,,26748470,445858,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
75,902,1,2,,26748470,445858,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
76,910,1,2,,26748470,445858,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
77,923,1,2,,26748470,445858,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
78,924,1,2,,26748470,445858,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
79,927,1,3,,26748470,445858,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
80,930,1,2,,26748470,445858,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
81,940,1,2,,26612156,445858,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
82,995,1,2,,26748470,445858,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
83,1030,2,1,,26748470,445858,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
84,1033,2,2,,11537687,445858,Inactive,216546.0,,,,NMR Based Screening Assay for the substrate binding domain of the chaperone DnaK,Screening,,
85,1376,1,2,,47193700,445858,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
86,1379,1,2,,26748470,445858,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
87,1385,2,2,,47193700,445858,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
88,1422,1,1,,26612156,445858,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
89,1422,1,1,,47193700,445858,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
90,1452,1,1,,26748470,445858,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
91,1454,1,1,,26748470,445858,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
92,1457,1,1,,26748470,445858,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
93,1458,1,1,,26748470,445858,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
94,1460,1,3,,26748470,445858,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
95,1463,1,1,,26748470,445858,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
96,1465,1,1,,47193700,445858,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
97,1467,1,3,,26748470,445858,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
98,1468,1,1,,26748470,445858,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
99,1469,1,1,,26748470,445858,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
100,1471,2,1,,26748470,445858,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
101,1476,2,1,,26748470,445858,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
102,1477,1,1,,26748470,445858,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
103,1478,2,1,,26748470,445858,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
104,1479,1,2,,26748470,445858,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
105,1490,2,1,,26748470,445858,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
106,1511,1,3,,47193700,445858,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
107,1519,1,3,,26748470,445858,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
108,1529,1,1,,47193700,445858,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
109,1530,1,1,,47193700,445858,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
110,1531,1,1,,47193700,445858,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
111,1532,1,1,,47193700,445858,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
112,1549,1,2,,11537687,445858,Inactive,89033149.0,,,,NMR Based Screening Assay for Novel Chemotypes against influenza A virus,Other,,
113,1552,1,3,,11537687,445858,Inactive,4507793.0,7334.0,,,NMR assay targeting the ubiquitin-proteasome system to modulate protein folding and degradation,Other,,
114,1554,1,1,,47193700,445858,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
115,1621,1,2,,47193700,445858,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
116,1626,1,2,,47193700,445858,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
117,1637,1,2,,11537687,445858,Inactive,,,,,NMR Based Screening Assay for Influenza A RNA Promoter,Other,,
118,1648,1,2,,11537687,445858,Inactive,159164579.0,,,,NMR Based Screening Assay For Novel Chemical Probes Targeting The FRB Domain of mTOR,Other,,
119,1662,1,2,,47193700,445858,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
120,1663,1,2,,47193700,445858,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
121,1672,1,3,,47193700,445858,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
122,1766,1,1,,26748470,445858,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
123,1766,1,1,,26748470,445858,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
124,1768,1,1,,26748470,445858,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
125,1768,1,1,,26748470,445858,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
126,1813,1,2,,47193700,445858,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
127,1814,1,2,,47193700,445858,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
128,1832,2,1,,47193700,445858,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
129,1850,2,1,,47193700,445858,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
130,1863,2,1,,47193700,445858,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
131,1865,1,1,,26748470,445858,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
132,1875,2,1,,47193700,445858,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
133,1885,2,1,,47193700,445858,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
134,1899,1,3,,47193700,445858,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
135,1903,2,3,,47193700,445858,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
136,1906,1,3,,47193700,445858,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
137,1910,1,2,,47193700,445858,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
138,1947,1,2,,47193700,445858,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
139,1948,1,1,,26748470,445858,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
140,1950,1,3,,47193700,445858,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
141,1956,1,1,,47193700,445858,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
142,1962,1,2,,47193700,445858,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
143,1974,1,2,,47193700,445858,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
144,1979,1,1,,47193700,445858,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
145,1987,1,2,,47193700,445858,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
146,2016,1,3,,47193700,445858,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
147,2023,1,3,,47193700,445858,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
148,2025,1,3,,47193700,445858,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
149,2029,1,3,,47193700,445858,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
150,2052,2,1,,47193700,445858,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
151,2057,1,2,,47193700,445858,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
152,2066,1,4,,47193700,445858,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
153,2094,1,2,,47193700,445858,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
154,2094,1,2,,47193700,445858,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
155,2094,1,2,,47193700,445858,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
156,2097,1,2,,47193700,445858,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
157,2098,1,1,,47193700,445858,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
158,2099,1,1,,47193700,445858,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
159,2101,1,1,,26748470,445858,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
160,2107,1,1,,26748470,445858,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
161,2112,1,1,,26748470,445858,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
162,2129,1,2,,47193700,445858,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
163,2130,1,3,,47193700,445858,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
164,2147,1,1,,26748470,445858,Inconclusive,221046486.0,,28.1838,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
165,2156,2,2,,47193700,445858,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
166,2174,1,3,,47193700,445858,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
167,2177,1,3,,47193700,445858,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
168,2216,1,3,,47193700,445858,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
169,2221,1,2,,47193700,445858,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
170,2227,1,2,,47193700,445858,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
171,2234,1,2,,47193700,445858,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
172,2235,1,2,,47193700,445858,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
173,2237,1,2,,47193700,445858,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
174,2239,1,2,,47193700,445858,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
175,2247,1,2,,47193700,445858,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
176,2280,2,3,,47193700,445858,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
177,2300,1,3,,47193700,445858,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
178,2380,1,2,,47193700,445858,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
179,2391,1,1,,47193700,445858,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
180,2435,1,2,,47193700,445858,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
181,2445,1,2,,47193700,445858,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
182,2451,1,2,,26748470,445858,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
183,2462,1,1,,47193700,445858,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
184,2462,1,1,,47193700,445858,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
185,2472,1,2,,26748470,445858,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
186,2517,2,1,,26748470,445858,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
187,2520,1,4,,47193700,445858,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
188,2521,1,3,,47193700,445858,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
189,2524,1,2,,47193700,445858,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
190,2528,1,2,,26748470,445858,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
191,2540,1,2,,47193700,445858,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
192,2544,1,2,,47193700,445858,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
193,2546,1,1,,26748470,445858,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
194,2549,1,1,,26748470,445858,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
195,2550,1,3,,47193700,445858,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
196,2551,1,1,,26748470,445858,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
197,2553,1,2,,47193700,445858,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
198,2557,1,3,,47193700,445858,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
199,2563,1,1,,47193700,445858,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
200,2599,1,2,,47193700,445858,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
201,2606,1,2,,47193700,445858,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
202,2629,1,1,,47193700,445858,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
203,2642,1,2,,47193700,445858,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
204,2648,1,2,,47193700,445858,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
205,2650,2,1,,47193700,445858,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
206,2661,1,1,,47193700,445858,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
207,2690,1,2,,47193700,445858,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
208,2716,1,1,,47193700,445858,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
209,2717,1,2,,47193700,445858,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
210,2718,1,1,,47193700,445858,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
211,2751,2,2,,47193700,445858,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
212,2796,1,4,,47193700,445858,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
213,2797,1,2,,47193700,445858,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
214,2805,2,2,,47193700,445858,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
215,2806,2,2,,47193700,445858,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
216,2825,1,2,,47193700,445858,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
217,82003,3,4,,103207410,445858,Unspecified,,,,,"Cell viability in TPA-induced superoxide (O2-) generation in human promyelocytic leukemia HL-60 cells, at 100 uM concentration",Other,10888327.0,
218,82327,3,4,,103207410,445858,Unspecified,,,,,"Inhibitory activity against TPA-induced superoxide (O2-) generation in human promyelocytic leukemia HL-60 cells, at 100 uM concentration",Other,10888327.0,
219,144377,7,1,,103207410,445858,Inactive,1172801.0,12972.0,,,Ability to induce NAD(P)H quinone reductase activity in cultured Hepa 1c1c7 murine hepatoma cells.,Other,9857096.0,
220,263688,5,8,,103207410,445858,Unspecified,401235.0,7299.0,,,Inhibitory activity against tyrosinase at 100uM,Other,16442796.0,
221,294172,3,10,,103207410,445858,Unspecified,6686057.0,,,,Inhibition of diphenolase activity of mushroom tyrosinase at 0.035 mM,Other,17287127.0,
222,308323,4,3,,103207410,445858,Active,,,0.0007700000000000001,Ki,Displacement of [125I]TZDM from human beta amyloid fibril 1-42,Confirmatory,17544669.0,
223,309363,3,3,,103207410,445858,Unspecified,,,,,Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear oedema at 0.3 umol/cm^2 after 6 hrs,Other,17768049.0,
224,312292,6,2,,103207410,445858,Unspecified,,,1000.0,IC50,Cytotoxicity against human K562 cells after 5 days by XTT assay,Confirmatory,18076140.0,
225,331670,3,3,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as trolox equivalents by ORAC-fluorescence assay,Other,18406135.0,
226,336952,5,1,,103207410,445858,Unspecified,,,,,Inhibition of bovine thymocytes protein tyrosine kinase assessed as angiotensin 1 phosphorylation,Other,2607357.0,
227,340663,3,3,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as trolox equivalents at 0.4 to 1.3 uM by ORAC-fluorescein assay,Other,18611049.0,
228,342752,3,4,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as DPPH free radical scavenging activity at 0.9 mM after 20 mins,Other,18590964.0,
229,342753,3,4,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as DPPH free radical scavenging activity at 1.8 mM after 10 mins,Other,18590964.0,
230,342754,3,4,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as DPPH free radical scavenging activity at 0.9 mM after 10 mins,Other,18590964.0,
231,342755,3,4,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as DPPH free radical scavenging activity at 1.8 mM after 20 mins,Other,18590964.0,
232,342756,3,4,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as DPPH free radical scavenging activity at 3.6 mM after 10 mins,Other,18590964.0,
233,342757,3,4,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as DPPH free radical scavenging activity at 3.6 mM after 20 mins,Other,18590964.0,
234,358173,10,1,,103207410,445858,Unspecified,,,,,Inhibition of p40 tyrosine kinase,Other,1479375.0,
235,371216,6,2,,103207410,445858,Unspecified,,,100.0,IC50,Inhibition of HIV1 integrase by ELISA,Confirmatory,18952420.0,
236,380793,3,10,,103207410,445858,Unspecified,8488960.0,3363.0,,,Displacement of [3H]LSD from human recombinant 5HT7 receptor expressed in CHO cells at 100 uM by liquid scintillation counting relative to control,Other,16643021.0,
237,383194,3,3,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as trolox equivalent at 0.3 to 1 uM by ORAC-fluorescein assay,Other,18343123.0,
238,388743,6,3,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity after 20 mins,Other,18976928.0,
239,395150,9,1,,103207410,445858,Unspecified,,,,,ABTS radical scavenging activity assessed as Trolox equivalent antioxidant capacity,Other,18403057.0,
240,397153,11,1,,103207410,445858,Unspecified,,,,,Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL preincubated for 1 hr before Cu2+ challenge,Other,11325231.0,
241,397183,3,3,,103207410,445858,Unspecified,,,,,DPPH radical scavenging activity assessed as Trolox equivalent antioxidant capacity at 50 uM after 40 mins,Other,19058883.0,
242,397184,3,3,,103207410,445858,Unspecified,,,,,ABTS radical scavenging activity assessed as Trolox equivalent antioxidant capacity at 50 uM by spectrophotometric analysis,Other,19058883.0,
243,397185,3,3,,103207410,445858,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,19058883.0,
244,397586,3,9,,103207410,445858,Unspecified,2497687.0,7941.0,,,Effect on human plasma LDL-PLA2 activity by LS-3B fluorescence spectrometry,Other,11325231.0,
245,398997,3,7,,103207410,445858,Inactive,,,,,Inhibition of xanthine oxidase at 50 ug/ml,Other,16309309.0,
246,399080,7,1,,103207410,445858,Active,,,,,Antioxidant activity assessed as DPPH scavenging activity,Other,16309309.0,
247,434955,1,2,,47193700,445858,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
248,434962,1,2,,47193700,445858,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
249,434973,1,3,,47193700,445858,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
250,434989,1,1,,47193700,445858,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
251,435003,1,3,,47193700,445858,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
252,435005,1,1,,47193700,445858,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
253,435022,2,2,,47193700,445858,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
254,435030,1,2,,47193700,445858,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
255,435030,1,2,,47193700,445858,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
256,447578,3,4,,103207410,445858,Unspecified,2498443.0,3065.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
257,447578,3,4,,103207410,445858,Unspecified,3334210.0,8841.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
258,447578,3,4,,103207410,445858,Unspecified,19865267.0,9734.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
259,447578,3,4,,103207410,445858,Unspecified,26394832.0,79885.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
260,447578,3,4,,103207410,445858,Unspecified,27734403.0,83933.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
261,447578,3,4,,103207410,445858,Unspecified,29839394.0,55869.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
262,447578,3,4,,103207410,445858,Unspecified,30913097.0,51564.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
263,447578,3,4,,103207410,445858,Unspecified,68068066.0,3066.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
264,447578,3,4,,103207410,445858,Unspecified,205371758.0,10013.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
265,447578,3,4,,103207410,445858,Unspecified,259016348.0,9759.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
266,447578,3,4,,103207410,445858,Unspecified,296434519.0,10014.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
267,449728,1,2,,47193700,445858,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
268,449739,1,2,,47193700,445858,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
269,449762,1,2,,47193700,445858,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
270,449763,1,3,,47193700,445858,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
271,449768,1,1,,47193700,445858,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
272,462270,8,5,,103207410,445858,Active,115449.0,759.0,2.89,Ki,Inhibition of human CA1 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
273,462271,8,5,,103207410,445858,Active,115456.0,760.0,2.4,Ki,Inhibition of human CA2 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
274,462272,8,5,,103207410,445858,Active,134047703.0,761.0,11.1,Ki,Inhibition of human CA3 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
275,462273,8,5,,103207410,445858,Active,115465.0,762.0,10.8,Ki,Inhibition of human CA4 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
276,462274,8,5,,103207410,445858,Active,461680.0,763.0,7.04,Ki,Inhibition of human CA5A by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
277,462275,8,5,,103207410,445858,Active,8928041.0,11238.0,10.5,Ki,Inhibition of human CA5B by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
278,462276,8,5,,103207410,445858,Active,116241278.0,765.0,8.45,Ki,Inhibition of human CA6 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
279,462277,8,5,,103207410,445858,Active,1168744.0,766.0,7.41,Ki,Inhibition of human CA7 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
280,462278,8,5,,103207410,445858,Active,83300925.0,768.0,9.87,Ki,Inhibition of human CA9 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
281,462279,8,5,,103207410,445858,Active,5915866.0,771.0,9.78,Ki,Inhibition of human CA12 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
282,462280,8,5,,103207410,445858,Active,30580372.0,71934.0,12.2,Ki,Inhibition of mouse CA13 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
283,462281,8,5,,103207410,445858,Active,8928036.0,23632.0,9.43,Ki,Inhibition of human CA14 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
284,462333,3,3,,103207410,445858,Unspecified,,,,,Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 30 uM after 72 hrs,Other,20189399.0,
285,462342,3,3,,103207410,445858,Unspecified,,,,,Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 30 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay,Other,20189399.0,
286,463079,1,2,,47193700,445858,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
287,463082,1,1,,47193700,445858,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
288,463104,1,2,,47193700,445858,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
289,463111,1,1,,47193700,445858,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
290,463141,1,2,,47193700,445858,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
291,463165,1,1,,47193700,445858,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
292,463190,1,2,,47193700,445858,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
293,463195,1,2,,47193700,445858,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
294,463210,1,2,,47193700,445858,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
295,463212,1,1,,47193700,445858,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
296,475504,3,3,,103207410,445858,Active,,,,,Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins,Other,19640715.0,
297,475505,3,3,,103207410,445858,Active,,,,,Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins,Other,19640715.0,
298,477408,5,4,,103207410,445858,Unspecified,,,2000.0,IC50,Inhibition of hyaluronidase,Confirmatory,20184336.0,
299,477928,3,4,,103207410,445858,Unspecified,,,,,Cytotoxicity against human PANC1 cells in nutrient-deprived condition assessed as preferential cell death after 24 hrs by trypan blue dye exclusion method,Other,20307087.0,
300,485270,1,1,,47193700,445858,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
301,485272,1,1,,47193700,445858,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
302,485273,2,1,,47193700,445858,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
303,485275,1,3,,47193700,445858,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
304,485281,1,1,,26748470,445858,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
305,485290,1,1,,26748470,445858,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
306,485317,1,2,,47193700,445858,Active,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
307,485346,1,1,,47193700,445858,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
308,485346,1,1,,47193700,445858,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
309,485350,1,2,,92124309,445858,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
310,488839,1,1,,57264356,445858,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
311,488839,1,1,,57264356,445858,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
312,488847,1,3,,47193700,445858,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
313,488862,1,1,,57264356,445858,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
314,488890,1,2,,47193700,445858,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
315,488895,1,2,,57264356,445858,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
316,488896,1,1,,57264356,445858,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
317,488922,1,2,,47193700,445858,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
318,488965,1,2,,57264356,445858,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
319,488966,1,1,,57264356,445858,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
320,488975,1,2,,47193700,445858,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
321,488977,1,2,,47193700,445858,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
322,489030,2,1,,47193700,445858,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
323,489031,2,1,,47193700,445858,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
324,492140,3,3,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as formazan formation induced absorbance changes at 25 ppm at 570 nm at 37 degC for 6 hrs by MTT assay,Other,20565070.0,
325,492953,1,1,,57264356,445858,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
326,492956,1,1,,57264356,445858,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
327,492972,1,1,,57264356,445858,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
328,493005,1,1,,47193700,445858,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
329,493008,1,1,,57264356,445858,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
330,493008,1,1,,57264356,445858,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
331,493008,1,1,,57264356,445858,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
332,493008,1,1,,57264356,445858,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
333,493011,1,1,,47193700,445858,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
334,493012,1,1,,47193700,445858,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
335,493033,1,2,,92124309,445858,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
336,493036,1,2,,47193700,445858,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
337,493087,1,1,,57264356,445858,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
338,493091,1,1,,47193700,445858,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
339,493098,1,1,,47193700,445858,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
340,493131,1,1,,57264356,445858,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
341,493160,1,1,,47193700,445858,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
342,493187,1,2,,47193700,445858,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
343,493244,1,1,,57264356,445858,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
344,493244,1,1,,57264356,445858,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
345,493244,1,1,,57264356,445858,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
346,493244,1,1,,57264356,445858,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
347,499282,2,3,,103207410,445858,Unspecified,,,,,Redox potential at pH 7.3 by differential pulse and cyclic voltametry,Other,20650639.0,
348,499283,2,3,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as inhibition of AAPH-induced lipid peroxidation in liposomes measured as Trolox equivalent antioxidant capacity,Other,20650639.0,
349,504326,1,2,,57264356,445858,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
350,504326,1,2,,57264356,445858,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
351,504327,1,1,,26748470,445858,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
352,504329,1,1,,57264356,445858,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
353,504332,1,1,,26748470,445858,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
354,504339,1,1,,47193700,445858,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
355,504357,1,1,,57264356,445858,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
356,504357,1,1,,57264356,445858,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
357,504406,1,1,,47193700,445858,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
358,504408,2,1,,47193700,445858,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
359,504411,1,1,,57264356,445858,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
360,504414,1,1,,57264356,445858,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
361,504414,1,1,,57264356,445858,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
362,504423,1,1,,57264356,445858,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
363,504441,1,1,,57264356,445858,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
364,504444,1,1,,47193700,445858,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
365,504454,1,3,,57264356,445858,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
366,504462,1,1,,47193700,445858,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
367,504490,1,2,,57264356,445858,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
368,504523,1,1,,57264356,445858,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
369,504523,1,1,,57264356,445858,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
370,504558,1,1,,57264356,445858,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
371,504577,2,2,,57264356,445858,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
372,504582,2,1,,57264356,445858,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
373,504621,1,1,,57264356,445858,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
374,504634,1,1,,57264356,445858,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
375,504648,1,1,,47193700,445858,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
376,504690,1,3,,47193700,445858,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
377,504692,2,2,,57264356,445858,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
378,504700,1,1,,57264356,445858,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
379,504700,1,1,,57264356,445858,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
380,504707,1,1,,57264356,445858,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
381,504707,1,1,,57264356,445858,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
382,504720,1,1,,47193700,445858,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
383,504734,1,1,,57264356,445858,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
384,504766,2,1,,57264356,445858,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
385,504770,1,2,,92124309,445858,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
386,504775,1,1,,57264356,445858,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
387,504803,1,1,,57264356,445858,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
388,504845,1,1,,47193700,445858,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
389,504847,1,1,,26748470,445858,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
390,504847,1,1,,47193700,445858,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
391,504865,1,1,,26748470,445858,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
392,504884,1,2,,57264356,445858,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
393,504891,1,1,,47193700,445858,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
394,504894,1,1,,47193700,445858,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
395,504937,1,2,,47193700,445858,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
396,540253,1,1,,47193700,445858,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
397,540253,1,1,,47193700,445858,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
398,540253,1,1,,47193700,445858,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
399,540263,1,1,,47193700,445858,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
400,540263,1,1,,47193700,445858,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
401,540267,1,1,,47193700,445858,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
402,540295,1,1,,57264356,445858,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
403,540299,1,2,,92124309,445858,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
404,540303,1,1,,47193700,445858,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
405,540303,1,1,,47193700,445858,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
406,540303,1,1,,47193700,445858,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
407,540308,1,1,,57264356,445858,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
408,540317,1,1,,47193700,445858,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
409,540336,1,1,,57264356,445858,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
410,540336,1,1,,57264356,445858,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
411,540364,1,2,,57264356,445858,Active,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
412,568834,4,3,,103207410,445858,Unspecified,,,111.6,IC50,Antioxidant activity assessed as residual DPPH radical scavenging activity after 45 mins by spectrophotometrically,Confirmatory,21216503.0,
413,568835,1,3,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as trolox equivalents of ABTS radical scavenging activity by TEAC assay,Other,21216503.0,
414,588335,1,1,,57264356,445858,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
415,588350,2,1,,57264356,445858,Inactive,,2395.0,,,Counterscreen for activators of the GAA850 frataxin promoter: luminescence-based cell-based high throughput screening assay to identify activators of the GAA30 frataxin promoter,Screening,,
416,588351,1,1,,57264356,445858,Inactive,,2395.0,,,Luminescence-based cell-based high throughput confirmation assay for activators of the GAA850 frataxin (FXN) promoter,Screening,,
417,588352,1,2,,57264356,445858,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
418,588354,1,1,,57264356,445858,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
419,588358,1,2,,57264356,445858,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
420,588405,1,1,,57264356,445858,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
421,588413,1,2,,47193700,445858,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
422,588436,1,1,,57264356,445858,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
423,588453,1,1,,47193700,445858,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
424,588456,1,1,,47193700,445858,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
425,588458,1,1,,57264356,445858,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
426,588473,1,1,,47193700,445858,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
427,588473,1,1,,47193700,445858,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
428,588475,1,2,,47193700,445858,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
429,588475,1,2,,47193700,445858,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
430,588478,1,2,,124812733,445858,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
431,588489,1,1,,57264356,445858,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
432,588492,1,1,,57264356,445858,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
433,588493,1,2,,57264356,445858,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
434,588497,1,2,,57264356,445858,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
435,588497,1,2,,57264356,445858,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
436,588497,1,2,,57264356,445858,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
437,588499,1,3,,57264356,445858,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
438,588499,1,3,,57264356,445858,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
439,588499,1,3,,57264356,445858,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
440,588501,1,2,,57264356,445858,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
441,588501,1,2,,57264356,445858,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
442,588501,1,2,,57264356,445858,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
443,588511,1,2,,47193700,445858,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
444,588519,1,2,,92124309,445858,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
445,588549,1,1,,57264356,445858,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
446,588579,1,1,,26748470,445858,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
447,588579,1,1,,47193700,445858,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
448,588590,1,1,,47193700,445858,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
449,588591,1,1,,47193700,445858,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
450,588621,1,1,,57264356,445858,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
451,588627,1,1,,47193700,445858,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
452,588664,1,2,,57264356,445858,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
453,588664,1,2,,57264356,445858,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
454,588674,1,2,,57264356,445858,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
455,588675,1,1,,47193700,445858,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
456,588676,1,1,,47193700,445858,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
457,588689,1,1,,57264356,445858,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
458,588692,2,1,,57264356,445858,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
459,588726,1,2,,57264356,445858,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
460,588727,1,1,,57264356,445858,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
461,588795,1,1,,47193700,445858,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
462,588814,1,3,,57264356,445858,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
463,588819,1,4,,57264356,445858,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
464,588832,1,1,,57264356,445858,Inactive,7300964.0,,,,Hedgehog Measured in Biochemical System Using Plate Reader - 2070-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
465,588850,1,1,,57264356,445858,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
466,588852,1,3,,57264356,445858,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
467,588855,1,1,,47193700,445858,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
468,588856,1,1,,47193700,445858,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
469,590194,3,3,,103207410,445858,Unspecified,,,250.0,EC50,Antioxidant activity assessed as DPPH radical scavenging activity by spectrophotometry,Confirmatory,21377874.0,
470,590195,6,5,,103207410,445858,Unspecified,6686057.0,,350.0,IC50,Inhibition of mushroom tyrosinase after 25 mins by spectrophotometry,Confirmatory,21377874.0,
471,592088,3,2,,103207410,445858,Active,,,0.2,IC50,Antihemorrhagic activity in ddY mouse assessed as inhibition of Protobothrops flavoviridis venom-induced hemorrhage incubated with compound for 10 mins measured after 24 hrs,Confirmatory,21388814.0,
472,592240,4,6,,103207410,445858,Inactive,126716.0,,,IC50,Inhibition of yeast alpha-glucosidase assessed as inhibition of p-nitrophenyl-alpha-D-glucopyranoside substrate hydrolysis after 35 mins by spectroscopy,Confirmatory,20879744.0,
473,592241,1,4,,103207410,445858,Active,,,,,Antihyperglycemic activity in po dosed diabetic KK-Ay mouse model,Other,20879744.0,
474,592242,1,4,,103207410,445858,Active,,,,,"Hypoglycemic activity in rat assessed as decrease in plasma glucose at 5 mg/kg, iv",Other,20879744.0,
475,592243,1,4,,103207410,445858,Active,,,,,"Hypoglycemic activity in rat assessed as increase in insulin concentration at 5 mg/kg, iv",Other,20879744.0,
476,592244,1,4,,103207410,445858,Unspecified,,,,,Hypoglycemic activity in rat L6 myotubes assessed as increase in 2-deoxyglucose transport at 25 uM relative to control,Other,20879744.0,
477,594382,1,11,,103207410,445858,Unspecified,74762622.0,338442.0,,,Displacement of [3H]nicotinic acid from human GPR109a receptor expressed in human HEK293T cells at 10 uM by liquid scintillation counting,Other,21167710.0,
478,602123,1,1,,57264356,445858,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
479,602141,1,1,,57264356,445858,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
480,602162,1,1,,57264356,445858,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
481,602163,1,1,,57264356,445858,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
482,602179,1,2,,47193700,445858,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
483,602229,1,1,,57264356,445858,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
484,602233,1,1,,47193700,445858,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
485,602244,1,2,,57264356,445858,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
486,602247,1,2,,57264356,445858,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
487,602248,1,2,,57264356,445858,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
488,602250,1,2,,57264356,445858,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
489,602252,1,1,,57264356,445858,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
490,602252,1,1,,57264356,445858,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
491,602261,1,1,,57264356,445858,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
492,602274,1,2,,57264356,445858,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
493,602281,1,1,,57264356,445858,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
494,602281,1,1,,57264356,445858,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
495,602310,1,2,,47193700,445858,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
496,602313,1,1,,47193700,445858,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
497,602314,1,2,,92124309,445858,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
498,602329,1,1,,57264356,445858,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
499,602332,1,1,,26748470,445858,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
500,602332,1,1,,47193700,445858,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
501,602340,1,2,,57264356,445858,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
502,602342,2,1,,57264356,445858,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
503,602346,1,1,,57264356,445858,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
504,602363,1,1,,57264356,445858,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
505,602393,1,1,,57264356,445858,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
506,602396,1,2,,57264356,445858,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
507,602399,1,2,,57264356,445858,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
508,602405,1,1,,57264356,445858,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
509,602410,1,1,,57264356,445858,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
510,602429,1,1,,57264356,445858,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
511,602438,1,1,,57264356,445858,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
512,602440,1,1,,57264356,445858,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
513,602449,1,2,,57264356,445858,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
514,602481,1,1,,57264356,445858,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
515,607593,3,3,,103207410,445858,Unspecified,,,100.0,IC50,Cytotoxicity against human U373 cells after 72 hrs by MTT assay,Confirmatory,21696954.0,
516,607594,3,3,,103207410,445858,Unspecified,,,68.0,IC50,Cytotoxicity against human OE21 cells after 72 hrs by MTT assay,Confirmatory,21696954.0,
517,607595,3,2,,103207410,445858,Unspecified,,,100.0,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,21696954.0,
518,607596,3,2,,103207410,445858,Unspecified,,,100.0,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,21696954.0,
519,607597,3,2,,103207410,445858,Unspecified,,,100.0,IC50,Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay,Confirmatory,21696954.0,
520,607598,3,2,,103207410,445858,Unspecified,,,95.0,IC50,Cytotoxicity against human LoVo cells after 72 hrs by MTT assay,Confirmatory,21696954.0,
521,607600,1,3,,103207410,445858,Inconclusive,,,,,Induction of human U373 cell death assessed as morphological changes at MTT assay-related IC50 after 72 hrs by quantitative video microscopy,Other,21696954.0,
522,607601,1,4,,103207410,445858,Inconclusive,,,,,Cytotoxicity against human U373 cells assessed as growth inhibition at MTT assay-related IC50 by quantitative video microscopy relative to control,Other,21696954.0,
523,623870,1,1,,57264356,445858,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
524,623870,1,1,,57264356,445858,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
525,623877,1,1,,57264356,445858,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
526,623901,1,1,,57264356,445858,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
527,624037,1,3,,57264356,445858,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
528,624038,1,3,,57264356,445858,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
529,624040,1,3,,57264356,445858,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
530,624125,1,4,,57264356,445858,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
531,624126,1,3,,57264356,445858,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
532,624127,1,2,,57264356,445858,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
533,624168,1,1,,57264356,445858,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
534,624169,1,1,,57264356,445858,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
535,624170,1,1,,47193700,445858,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
536,624171,1,1,,47193700,445858,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
537,624172,1,1,,47193700,445858,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
538,624173,1,3,,47193700,445858,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
539,624178,1,1,,47193700,445858,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
540,624202,1,1,,47193700,445858,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
541,624204,1,2,,57264356,445858,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
542,624246,1,1,,47193700,445858,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
543,624256,1,2,,57264356,445858,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
544,624263,1,1,,47193700,445858,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
545,624263,1,1,,47193700,445858,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
546,624267,1,2,,57264356,445858,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
547,624267,1,2,,57264356,445858,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
548,624268,1,3,,57264356,445858,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
549,624288,1,1,,47193700,445858,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
550,624291,1,1,,47193700,445858,Inactive,121312.0,1081.0,,Potency,qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy,Confirmatory,,
551,624296,1,1,,47193700,445858,Inconclusive,7705682.0,51053.0,0.0065,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
552,624297,1,1,,47193700,445858,Inconclusive,7705682.0,51053.0,0.92,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
553,624304,1,2,,57264356,445858,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
554,624330,1,2,,57264356,445858,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
555,624349,1,2,,92124309,445858,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
556,624352,1,1,,57264356,445858,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
557,624354,1,1,,57264356,445858,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
558,624377,1,1,,57264356,445858,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
559,624416,1,1,,57264356,445858,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
560,624417,1,1,,47193700,445858,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
561,624418,1,1,,47193700,445858,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
562,624463,1,1,,47193700,445858,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
563,624464,1,1,,47193700,445858,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
564,624465,1,1,,47193700,445858,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
565,624466,1,3,,57264356,445858,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
566,624467,1,1,,57264356,445858,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
567,624483,1,1,,57264356,445858,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
568,624606,1,9,,103207410,445858,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
569,624608,3,2,,103207410,445858,Unspecified,136731.0,54657.0,,,Specific activity of expressed human recombinant UGT1A4,Other,10836148.0,
570,624616,1,8,,103207410,445858,Unspecified,332278237.0,7366.0,,,Specific activity of expressed human recombinant UGT2B15,Other,10836148.0,
571,625144,5,5,,103207410,445858,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
572,625145,4,7,,103207410,445858,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
573,625146,5,5,,103207410,445858,Active,126397.0,100009114.0,3.975,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
574,625147,4,7,,103207410,445858,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
575,625148,4,7,,103207410,445858,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
576,625149,4,7,,103207410,445858,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
577,625150,5,5,,103207410,445858,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
578,625151,4,7,,103207410,445858,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
579,625152,4,7,,103207410,445858,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
580,625153,4,7,,103207410,445858,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
581,625154,4,7,,103207410,445858,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
582,625155,4,7,,103207410,445858,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
583,625156,1,9,,103207410,445858,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
584,625157,6,2,,103207410,445858,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
585,625158,3,4,,103207410,445858,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
586,625159,5,5,,103207410,445858,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
587,625160,1,9,,103207410,445858,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
588,625161,4,7,,103207410,445858,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
589,625162,4,7,,103207410,445858,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
590,625163,4,7,,103207410,445858,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
591,625164,1,6,,103207410,445858,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
592,625165,3,4,,103207410,445858,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
593,625166,3,4,,103207410,445858,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
594,625167,5,5,,103207410,445858,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
595,625168,4,7,,103207410,445858,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
596,625169,1,6,,103207410,445858,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
597,625170,3,4,,103207410,445858,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
598,625171,4,7,,103207410,445858,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
599,625172,4,7,,103207410,445858,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
600,625173,5,5,,103207410,445858,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
601,625174,5,5,,103207410,445858,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
602,625175,5,5,,103207410,445858,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
603,625176,1,9,,103207410,445858,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
604,625177,5,5,,103207410,445858,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
605,625178,5,5,,103207410,445858,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
606,625179,1,9,,103207410,445858,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
607,625180,5,5,,103207410,445858,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
608,625181,5,5,,103207410,445858,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
609,625182,5,5,,103207410,445858,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
610,625183,5,5,,103207410,445858,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
611,625184,5,5,,103207410,445858,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
612,625185,5,5,,103207410,445858,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
613,625186,5,5,,103207410,445858,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
614,625187,5,5,,103207410,445858,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
615,625188,1,9,,103207410,445858,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
616,625189,1,7,,103207410,445858,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
617,625190,4,5,,103207410,445858,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
618,625191,4,7,,103207410,445858,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
619,625192,4,7,,103207410,445858,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
620,625193,5,5,,103207410,445858,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
621,625194,4,7,,103207410,445858,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
622,625195,4,7,,103207410,445858,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
623,625196,5,6,,103207410,445858,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
624,625197,3,4,,103207410,445858,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
625,625198,4,7,,103207410,445858,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
626,625199,4,7,,103207410,445858,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
627,625200,4,7,,103207410,445858,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
628,625201,4,7,,103207410,445858,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
629,625202,4,7,,103207410,445858,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
630,625203,4,7,,103207410,445858,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
631,625204,4,7,,103207410,445858,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
632,625205,4,7,,103207410,445858,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
633,625206,4,7,,103207410,445858,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
634,625207,4,7,,103207410,445858,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
635,625208,5,5,,103207410,445858,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
636,625209,4,7,,103207410,445858,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
637,625210,3,4,,103207410,445858,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
638,625211,1,6,,103207410,445858,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
639,625212,3,4,,103207410,445858,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
640,625213,4,7,,103207410,445858,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
641,625214,1,9,,103207410,445858,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
642,625215,3,4,,103207410,445858,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
643,625216,3,4,,103207410,445858,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
644,625217,4,7,,103207410,445858,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
645,625218,4,7,,103207410,445858,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
646,625219,3,4,,103207410,445858,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
647,625220,4,7,,103207410,445858,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
648,625221,4,7,,103207410,445858,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
649,625222,4,7,,103207410,445858,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
650,625223,4,7,,103207410,445858,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
651,625224,3,4,,103207410,445858,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
652,625225,3,4,,103207410,445858,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
653,625226,4,7,,103207410,445858,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
654,625227,4,7,,103207410,445858,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
655,625228,4,7,,103207410,445858,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
656,625229,5,5,,103207410,445858,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
657,625230,1,6,,103207410,445858,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
658,625231,4,7,,103207410,445858,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
659,625232,1,9,,103207410,445858,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
660,625233,4,7,,103207410,445858,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
661,625234,3,4,,103207410,445858,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
662,625235,4,7,,103207410,445858,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
663,625236,5,5,,103207410,445858,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
664,625237,4,7,,103207410,445858,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
665,625238,4,7,,103207410,445858,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
666,625239,4,7,,103207410,445858,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
667,625240,1,9,,103207410,445858,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
668,625241,4,7,,103207410,445858,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
669,625242,4,7,,103207410,445858,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
670,625243,5,5,,103207410,445858,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
671,625244,5,5,,103207410,445858,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
672,625245,5,5,,103207410,445858,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
673,625246,1,9,,103207410,445858,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
674,625247,5,5,,103207410,445858,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
675,625248,5,5,,103207410,445858,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
676,625249,5,5,,103207410,445858,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
677,625250,5,5,,103207410,445858,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
678,625251,5,5,,103207410,445858,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
679,625252,4,7,,103207410,445858,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
680,625253,4,7,,103207410,445858,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
681,625254,4,7,,103207410,445858,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
682,625255,4,7,,103207410,445858,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
683,625256,4,7,,103207410,445858,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
684,625257,4,7,,103207410,445858,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
685,625258,4,7,,103207410,445858,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
686,625259,4,7,,103207410,445858,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
687,625260,3,4,,103207410,445858,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
688,625261,3,4,,103207410,445858,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
689,625262,3,4,,103207410,445858,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
690,625263,4,7,,103207410,445858,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
691,625264,3,4,,103207410,445858,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
692,625265,1,6,,103207410,445858,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
693,625266,3,4,,103207410,445858,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
694,625267,3,4,,103207410,445858,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
695,625268,4,2,,103207410,445858,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
696,625268,4,2,,103207410,445858,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
697,625268,4,2,,103207410,445858,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
698,625268,4,2,,103207410,445858,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
699,625269,4,7,,103207410,445858,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
700,625270,4,7,,103207410,445858,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
701,625271,5,5,,103207410,445858,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
702,625272,3,4,,103207410,445858,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
703,625273,4,6,,103207410,445858,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
704,625274,1,6,,103207410,445858,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
705,625275,3,4,,103207410,445858,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
706,635414,5,5,,103207410,445858,Unspecified,14916521.0,,100.0,IC50,Inhibition of electric eel AChE using acetylcholine chloride as substrate preincubated for 15 mins by Ellman's method,Confirmatory,22041172.0,
707,635415,5,5,,103207410,445858,Inconclusive,75074633.0,,,IC50,Inhibition of equine serum BuChE using butyrylthiocholine chloride as substrate preincubated for 15 mins by Ellman's method,Confirmatory,22041172.0,
708,635417,5,5,,103207410,445858,Inconclusive,75074633.0,,,IC50,Inhibition of equine serum BuChE using acetylcholine as substrate preincubated for 15 mins by Ellman's method,Confirmatory,22041172.0,
709,635418,1,4,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as trolox equivalent of APPH-induced radical scavenging activity at 0.5 to 10 uM measured every 60 sec for 4 hrs by ORAC fluorescence assay relative to trolox,Other,22041172.0,
710,635419,1,4,,103207410,445858,Unspecified,,,,,Inhibition of self-mediated amyloid beta (1 to 42) aggregation at 20 uM after 48 hrs by thioflavin T fluorescence assay,Other,22041172.0,
711,642414,1,9,,103207410,445858,Unspecified,544257.0,2099.0,,,Estrogenic activity at ERalpha in human MVLN cells at 100 ug/mL after 24 hrs by luciferase reporter gene assay relative to E2,Other,22137340.0,
712,642415,1,9,,103207410,445858,Unspecified,544257.0,2099.0,,,Estrogenic activity at ERalpha in human MVLN cells at 20 ug/mL after 24 hrs by luciferase reporter gene assay relative to E2,Other,22137340.0,
713,651550,1,1,,47193700,445858,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
714,651560,1,1,,57264356,445858,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
715,651572,1,2,,57264356,445858,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
716,651602,1,1,,57264356,445858,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
717,651602,1,1,,57264356,445858,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
718,651602,1,1,,57264356,445858,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
719,651635,1,3,,47193700,445858,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
720,651636,1,1,,57264356,445858,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
721,651640,1,1,,57264356,445858,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
722,651644,1,1,,47193700,445858,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
723,651647,1,1,,57264356,445858,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
724,651654,1,1,,57264356,445858,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
725,651658,1,1,,57264356,445858,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
726,651661,2,1,,57264356,445858,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
727,651687,1,1,,57264356,445858,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
728,651699,1,1,,57264356,445858,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
729,651699,1,1,,57264356,445858,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
730,651702,1,2,,57264356,445858,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
731,651704,2,1,,57264356,445858,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
732,651710,1,1,,57264356,445858,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
733,651711,2,1,,57264356,445858,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
734,651718,1,2,,57264356,445858,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
735,651719,1,2,,57264356,445858,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
736,651723,1,1,,57264356,445858,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
737,651724,1,1,,47193700,445858,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
738,651725,1,1,,47193700,445858,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
739,651768,1,2,,47193700,445858,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
740,651800,1,1,,57264356,445858,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
741,651819,1,1,,47193700,445858,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
742,651820,1,1,,47193700,445858,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
743,651821,2,4,,57264356,445858,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
744,651957,1,1,,57264356,445858,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
745,651958,1,1,,57264356,445858,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
746,651965,1,1,,47193700,445858,Inconclusive,2668494.0,,19.9526,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
747,651999,1,1,,57264356,445858,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
748,652010,1,1,,57264356,445858,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
749,652017,1,1,,57264356,445858,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
750,652025,1,1,,47193700,445858,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
751,652039,1,1,,57264356,445858,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
752,652048,1,2,,47193700,445858,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
753,652051,1,1,,47193700,445858,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
754,652054,1,1,,47193700,445858,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
755,652067,1,4,,57264356,445858,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
756,652104,1,1,,47193700,445858,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
757,652105,1,1,,47193700,445858,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
758,652106,1,1,,47193700,445858,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
759,652126,1,3,,57264356,445858,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
760,652162,2,1,,57264356,445858,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
761,652163,1,1,,57264356,445858,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
762,652197,1,1,,57264356,445858,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
763,652257,1,1,,57264356,445858,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
764,668898,1,3,,103207410,445858,Unspecified,,,,,Inhibition of nitrite level in LPS-induced mouse RAW264.7 cells at 5 uM by Griess assay relative to LPS treated control,Other,21183258.0,
765,668899,1,3,,103207410,445858,Unspecified,,,,,Inhibition of nitrite level in LPS-induced mouse RAW264.7 cells at 50 uM by Griess assay relative to LPS treated control,Other,21183258.0,
766,668900,1,3,,103207410,445858,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells at 5 uM by MTT assay,Other,21183258.0,
767,668901,1,3,,103207410,445858,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells at 50 uM by MTT assay,Other,21183258.0,
768,686940,1,1,,57264356,445858,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
769,686964,1,1,,57264356,445858,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
770,686970,1,2,,47193700,445858,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
771,686971,1,2,,47193700,445858,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
772,686978,1,1,,26748470,445858,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
773,686978,1,1,,47193700,445858,Inactive,79154014.0,55775.0,3.6626,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
774,686979,1,1,,26748470,445858,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
775,686979,1,1,,47193700,445858,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
776,686996,1,1,,57264356,445858,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
777,687014,1,1,,57264356,445858,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
778,687016,1,1,,57264356,445858,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
779,697852,1,7,,103207410,445858,Unspecified,14916521.0,,,,Inhibition of electric eel AChE at 2 mg/ml by Ellman's method,Other,23062825.0,
780,697853,1,7,,103207410,445858,Unspecified,21362409.0,100033901.0,,,Inhibition of horse BChE at 2 mg/ml by Ellman's method,Other,23062825.0,
781,720504,1,1,,47193700,445858,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
782,720508,1,1,,57264356,445858,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
783,720509,1,1,,57264356,445858,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
784,720511,1,1,,57264356,445858,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
785,720532,1,1,,26748470,445858,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
786,720533,1,1,,26748470,445858,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
787,720542,1,2,,47193700,445858,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
788,720543,1,1,,57264356,445858,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
789,720551,1,2,,47193700,445858,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
790,720553,1,2,,47193700,445858,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
791,720579,2,1,,26748470,445858,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
792,720579,2,1,,47193700,445858,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
793,720580,1,1,,26748470,445858,Inconclusive,222762.0,3707576.0,5.0119,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
794,720580,1,1,,47193700,445858,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
795,720582,1,1,,57264356,445858,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
796,720596,1,1,,57264356,445858,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
797,720648,1,1,,57264356,445858,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
798,720700,1,4,,57264356,445858,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
799,720702,1,1,,57264356,445858,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
800,720704,1,4,,57264356,445858,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
801,720707,1,2,,47193700,445858,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
802,720708,1,2,,47193700,445858,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
803,720709,1,2,,47193700,445858,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
804,720711,1,2,,47193700,445858,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
805,720717,1,3,,92124309,445858,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
806,733992,1,2,,103207410,445858,Inactive,,,,,Inhibition of mushroom tyrosinase using L-DOPA substrate at 50 to 100 uM incubated for 10 mins,Other,23305921.0,
807,733995,1,3,,103207410,445858,Active,,,,,Antioxidant activity assessed as DPPH radical scavenging activity by UV/Visible spectrophotometry,Other,23305921.0,
808,736009,3,2,,103207410,445858,Unspecified,,,62.4,IC50,Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins by microplate reader,Confirmatory,23356964.0,
809,738360,1,3,,103207410,445858,Unspecified,,,2700.0,IC50,Inhibition of ADP-induced rabbit platelet aggregation compound pre-incubated in rabbit liver microsomal suspension,Confirmatory,23466230.0,
810,743126,1,1,,57264356,445858,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
811,743255,1,1,,47193700,445858,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
812,743266,1,2,,47193700,445858,Inactive,296080761.0,5745.0,8.9125,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
813,743269,1,1,,57264356,445858,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
814,743269,1,1,,57264356,445858,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
815,743279,1,2,,47193700,445858,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
816,743398,1,1,,57264356,445858,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
817,768928,1,5,,103207410,445858,Inactive,135807.0,2147.0,,,Inhibition of human thrombin amidolytic activity using D-Phe-Pip-Arg-pNA as substrate at 0.1 to 1000 uM preincubated for 10 mins followed by substrate addition measured every 12 secs for 10 mins by spectrophotometric analysis,Other,24610996.0,
818,775860,1,2,,103207410,445858,Active,112927.0,351.0,,,Inhibition of amyloid beta (1 to 42) (unknown origin) oligomerization at 10 uM after 2 hrs by SDS-PAGE analysis,Other,24076170.0,
819,775861,1,2,,103207410,445858,Unspecified,112927.0,351.0,,,Inhibition of amyloid beta (unknown origin) fibril formation at 10 uM by thioflavin T fluorescent dye assay,Other,24076170.0,
820,926569,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020930,Other,,
821,926570,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020930,Other,,
822,926571,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020930,Other,,
823,926572,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020930,Other,,
824,926573,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020930,Other,,
825,926574,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020930,Other,,
826,926575,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020930,Other,,
827,926576,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020930,Other,,
828,926577,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020930,Other,,
829,926578,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020930,Other,,
830,930184,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020930,Other,,
831,930185,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020930,Other,,
832,930186,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020930,Other,,
833,930187,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020930,Other,,
834,930188,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020930,Other,,
835,930189,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020930,Other,,
836,930190,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020930,Other,,
837,930191,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020930,Other,,
838,930192,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020930,Other,,
839,930193,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020930,Other,,
840,930194,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020930,Other,,
841,930195,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020930,Other,,
842,930196,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020930,Other,,
843,930197,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020930",Other,,
844,930198,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020930,Other,,
845,930199,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020930,Other,,
846,930200,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020930,Other,,
847,932217,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020930,Other,,
848,932218,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020930,Other,,
849,935214,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020930,Other,,
850,935215,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020930",Other,,
851,935216,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020930,Other,,
852,935217,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020930,Other,,
853,935218,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020930,Other,,
854,935219,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020930,Other,,
855,935220,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020930,Other,,
856,935221,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020930,Other,,
857,935222,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020930,Other,,
858,973261,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020930,Other,,
859,973262,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020930,Other,,
860,973263,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020930,Other,,
861,973264,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020930,Other,,
862,973265,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020930,Other,,
863,973266,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020930,Other,,
864,973267,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020930,Other,,
865,973268,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020930,Other,,
866,973269,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020930,Other,,
867,973270,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020930,Other,,
868,973271,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020930,Other,,
869,973903,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020930,Other,,
870,973904,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020930,Other,,
871,973905,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020930,Other,,
872,973906,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020930,Other,,
873,973907,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020930,Other,,
874,973908,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020930,Other,,
875,973909,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020930,Other,,
876,973910,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020930,Other,,
877,974246,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020930,Other,,
878,974247,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020930,Other,,
879,974248,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020930,Other,,
880,974249,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020930,Other,,
881,974250,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020930,Other,,
882,974251,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020930,Other,,
883,974252,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020930,Other,,
884,974253,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020930,Other,,
885,974254,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020930,Other,,
886,974255,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020930,Other,,
887,974256,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020930,Other,,
888,974257,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020930,Other,,
889,974258,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020930,Other,,
890,976281,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020930,Other,,
891,976282,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020930,Other,,
892,976283,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020930,Other,,
893,976284,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020930,Other,,
894,976285,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020930,Other,,
895,976286,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020930,Other,,
896,977599,1,1,,103207410,445858,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
897,977602,1,2,,103207410,445858,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
898,1015917,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020930",Other,,
899,1015918,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020930",Other,,
900,1015919,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020930",Other,,
901,1015920,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020930",Other,,
902,1015921,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020930",Other,,
903,1015922,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020930",Other,,
904,1015923,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020930,Other,,
905,1015924,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020930",Other,,
906,1017646,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020930,Other,,
907,1017647,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020930",Other,,
908,1017648,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020930",Other,,
909,1017649,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020930",Other,,
910,1017650,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020930",Other,,
911,1017651,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020930",Other,,
912,1017652,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020930",Other,,
913,1018236,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020930",Other,,
914,1018237,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020930",Other,,
915,1018238,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020930",Other,,
916,1018239,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020930",Other,,
917,1018240,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020930",Other,,
918,1018241,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020930",Other,,
919,1018242,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020930",Other,,
920,1018243,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020930",Other,,
921,1018244,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020930",Other,,
922,1018245,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020930",Other,,
923,1018246,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020930",Other,,
924,1018247,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020930",Other,,
925,1018248,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020930",Other,,
926,1018249,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020930",Other,,
927,1018250,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020930,Other,,
928,1018251,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020930,Other,,
929,1018252,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020930",Other,,
930,1018253,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020930",Other,,
931,1018254,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020930",Other,,
932,1018255,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020930",Other,,
933,1018256,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020930,Other,,
934,1018257,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020930",Other,,
935,1018258,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020930",Other,,
936,1018259,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020930",Other,,
937,1018260,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020930",Other,,
938,1018261,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020930,Other,,
939,1018262,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020930",Other,,
940,1018263,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020930",Other,,
941,1018264,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020930",Other,,
942,1018265,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020930",Other,,
943,1018266,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020930",Other,,
944,1018267,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020930",Other,,
945,1018268,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020930",Other,,
946,1020140,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020930,Other,,
947,1020723,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020930",Other,,
948,1020724,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020930",Other,,
949,1020725,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020930",Other,,
950,1020726,1,3,,103207410,445858,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020930,Other,,
951,1020727,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020930",Other,,
952,1020728,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020930",Other,,
953,1020729,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020930",Other,,
954,1020730,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020930",Other,,
955,1020731,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020930",Other,,
956,1020732,1,3,,103207410,445858,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020930",Other,,
957,1053175,2,1,,124812733,445858,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
958,1053197,1,1,,57264356,445858,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
959,1062030,1,1,,103207410,445858,Unspecified,,,100.0,IC50,Inhibition of Streptococcus mutans OMZ65 recombinant sortase A delta-40 mutant using Dabcyl-QALPETGEE-Edans as substrate after 1 hr by fluorescence spectrophotometry,Confirmatory,24360605.0,
960,1070388,1,1,,103207410,445858,Inactive,,,,,Neuroprotective activity in mouse HT22 cells assessed as reduction of t-BOOH-induced oxidative stress at 40 uM preincubated for 3 hrs followed by t-BOOH induction measured after 20 hrs by MTT assay,Other,24245939.0,
961,1070389,1,1,,103207410,445858,Inactive,,,,,Neuroprotective activity in mouse HT22 cells assessed as reduction of t-BOOH-induced oxidative stress at 40 uM preincubated for 3 hrs followed by t-BOOH induction measured for 20 hrs by time-resolved ECIS analysis,Other,24245939.0,
962,1070390,1,1,,103207410,445858,Unspecified,,,,,Cytotoxicity against mouse HT22 cells assessed as cell viability at 40 uM after 24 hrs by MTT assay,Other,24245939.0,
963,1079931,1,1,,103207410,445858,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
964,1079932,1,1,,103207410,445858,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
965,1079933,1,1,,103207410,445858,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
966,1079934,1,1,,103207410,445858,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
967,1079935,1,1,,103207410,445858,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
968,1079936,1,1,,103207410,445858,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
969,1079937,1,1,,103207410,445858,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
970,1079938,1,1,,103207410,445858,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
971,1079939,1,1,,103207410,445858,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
972,1079940,1,1,,103207410,445858,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
973,1079941,1,1,,103207410,445858,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
974,1079942,1,1,,103207410,445858,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
975,1079943,1,1,,103207410,445858,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
976,1079944,1,1,,103207410,445858,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
977,1079945,1,1,,103207410,445858,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
978,1079946,1,1,,103207410,445858,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
979,1079947,1,1,,103207410,445858,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
980,1079948,1,1,,103207410,445858,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
981,1079949,1,1,,103207410,445858,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
982,1082387,1,1,,103207410,445858,Active,,,,,Increase in lignin content in Pisum sativum (pea) roots at 1 mM added to nutrient medium measured 5 to 15 days post onset of compound treatment,Other,21870840.0,
983,1082388,1,1,,103207410,445858,Active,,,,,Reduction in PAL activity in Pisum sativum (pea) roots at 1 MM added to nutrient medium measured 7 days post onset of compound treatment,Other,21870840.0,
984,1082390,1,1,,103207410,445858,Active,,,,,Increase in quinate content in Pisum sativum (pea) leaves at 1 mM added to nutrient medium measured 5 to 15 days post onset of compound treatment by ion chromatography,Other,21870840.0,
985,1082391,1,1,,103207410,445858,Active,,,,,Induction of ADH protein enzyme expression in Pisum sativum (pea) roots at 1 mM added to nutrient medium measured 5 to 15 days post onset of compound treatment by immunoblot,Other,21870840.0,
986,1082392,1,1,,103207410,445858,Active,,,,,Induction of PDC protein expression in Pisum sativum (pea) roots at 1 mM added to nutrient medium measured 5 to 15 days post onset of compound treatment by immunoblot,Other,21870840.0,
987,1082393,1,1,,103207410,445858,Active,,,,,Increase in starch content in Pisum sativum (pea) leaves at 1 mM added to nutrient medium measured 5 to 15 days post onset of compound treatment by capillary electrophoresis method,Other,21870840.0,
988,1082394,1,1,,103207410,445858,Active,,,,,Increase in soluble sugars content in Pisum sativum (pea) leaves at 1 mM added to nutrient medium measured 5 to 15 days post onset of compound treatment by capillary electrophoresis method,Other,21870840.0,
989,1082395,1,1,,103207410,445858,Inactive,,,,,Effect on starch content in Pisum sativum (pea) roots at 1 mM added to nutrient medium measured 5 to 15 days post onset of compound treatment by capillary electrophoresis method,Other,21870840.0,
990,1082396,1,1,,103207410,445858,Inactive,,,,,Effect on sucrose content in Pisum sativum (pea) roots at 1 mM added to nutrient medium measured 5 to 15 days post onset of compound treatment by capillary electrophoresis method,Other,21870840.0,
991,1082397,1,1,,103207410,445858,Active,,,,,Growth inhibition in Pisum sativum (pea) assessed as shoot growth arrest at 1 mM added to nutrient medium measured within 10 days post onset of compound treatment,Other,21870840.0,
992,1082398,1,1,,103207410,445858,Active,,,,,Growth inhibition in Pisum sativum (pea) assessed as root elongation arrest at 1 mM added to nutrient medium measured within 1 day post onset of compound treatment,Other,21870840.0,
993,1082399,1,1,,103207410,445858,Active,,,,,Drug level in Pisum sativum (pea) leaves at 1 mM added to nutrient medium measured 5 to 15 days post onset of compound treatment by HPLC method,Other,21870840.0,
994,1082420,1,1,,103207410,445858,Active,,,,,Drug level in Pisum sativum (pea) roots at 1 mM added to nutrient medium measured 5 to 15 days post onset of compound treatment by HPLC method,Other,21870840.0,
995,1083149,1,1,,103207410,445858,Unspecified,,,,,Nematotoxic activity against freshly hatched Meloidogyne incognita J2 (root-knot nematode) isolated from tomato roots assessed as induction of nematode paralysis measured 24 hr after immersion in compound test solutions,Other,23136941.0,
996,1083151,1,1,,103207410,445858,Unspecified,,,,,Antifungal activity against Phaeomoniella chlamydospora assessed as growth inhibition at 500 uM measured after 1 to 10 days relative to control,Other,23145924.0,
997,1083154,1,1,,103207410,445858,Unspecified,,,,,Antifungal activity against Diplodia seriata BoF98-1 assessed as growth inhibition measured after 1 to 10 days,Other,23145924.0,
998,1083155,1,1,,103207410,445858,Unspecified,,,,,Antifungal activity against Diplodia seriata BoF99-1 assessed as growth inhibition measured after 1 to 10 days,Other,23145924.0,
999,1083156,1,1,,103207410,445858,Unspecified,,,,,Antifungal activity against Diplodia seriata LAT28 assessed as growth inhibition measured after 1 to 10 days,Other,23145924.0,
1000,1083157,1,1,,103207410,445858,Unspecified,,,,,Antifungal activity against Lasiodiplodia theobromae CBS116460 assessed as growth inhibition measured after 1 to 10 days,Other,23145924.0,
1001,1083158,1,1,,103207410,445858,Unspecified,,,,,Antifungal activity against Diplodia seriata PLU03 assessed as growth inhibition measured after 1 to 10 days,Other,23145924.0,
1002,1083159,1,1,,103207410,445858,Unspecified,,,,,Antifungal activity against Diplodia mutila BRA08 assessed as growth inhibition measured after 1 to 10 days,Other,23145924.0,
1003,1083160,1,1,,103207410,445858,Unspecified,,,,,Antifungal activity against Neofusicoccum luteum CBS110299 assessed as growth inhibition measured after 1 to 10 days,Other,23145924.0,
1004,1083161,1,1,,103207410,445858,Unspecified,,,,,Antifungal activity against Neofusicoccum parvum PER20 assessed as growth inhibition measured after 1 to 10 days,Other,23145924.0,
1005,1083162,1,1,,103207410,445858,Unspecified,,,,,Antifungal activity against Neofusicoccum parvum Bp0014 assessed as growth inhibition measured after 1 to 10 days,Other,23145924.0,
1006,1083163,1,1,,103207410,445858,Unspecified,,,,,Antifungal activity against Botryosphaeria dothidea OGE14 assessed as growth inhibition measured after 1 to 10 days relative to control,Other,23145924.0,
1007,1083168,1,1,,103207410,445858,Unspecified,,,,,Antifungal activity against Eutypa lata BX1-10 assessed as growth inhibition at 500 uM measured after 1 to 10 days relative to control,Other,23145924.0,
1008,1083169,1,1,,103207410,445858,Unspecified,,,,,Antifungal activity against Neofusicoccum parvum assessed as growth inhibition at 500 uM measured after 1 to 10 days relative to control,Other,23145924.0,
1009,1083170,1,1,,103207410,445858,Unspecified,,,,,Antifungal activity against Diplodia seriata assessed as growth inhibition at 500 uM measured after 1 to 10 days relative to control,Other,23145924.0,
1010,1083171,1,1,,103207410,445858,Inactive,,,,,Antifungal activity against Togninia minima SO21 assessed as susceptibility at 500 uM measured after 1 to 10 days,Other,23145924.0,
1011,1085233,2,3,,103207410,445858,Unspecified,126716.0,,300.0,IC50,Inhibition of yeast alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 10 min before substrate addition and measured after 10 min by spectrophotometry,Confirmatory,,
1012,1085313,3,1,,103207410,445858,Unspecified,,,,,Antioxidant activity against AAPH-induced hemolysis in Homo sapiens (human) RBC assessed as inhibition time at 10 uM by spectrophotometry,Other,,
1013,1085314,1,2,,103207410,445858,Unspecified,,,50.13,IC50,Antioxidant activity assessed as DPPH scavenging activity after 30 min by UV-vis spectroscopy,Confirmatory,,
1014,1099186,1,2,,103207410,445858,Unspecified,,,,,Antimicrobial activity against Athelia rolfsii assessed as growth inhibition at 100 ppm by agar dilution method,Other,,
1015,1099189,1,2,,103207410,445858,Unspecified,,,,,Antimicrobial activity against Pythium sp. assessed as growth inhibition at 100 ppm by agar dilution method,Other,,
1016,1100608,1,1,,103207410,445858,Inactive,,,,,Antibacterial activity against Ralstonia solanacearum grown on potato semi-synthetic agar medium at 5 umol/disk by paper disk method,Other,84.0,
1017,1100609,1,1,,103207410,445858,Inactive,,,,,Antibacterial activity against Ralstonia solanacearum grown on potato semi-synthetic agar medium at 0.5 umol/disk by paper disk method,Other,84.0,
1018,1107734,1,1,,103207410,445858,Inactive,,,,,Decrease in Botryosphaeria dothidea ligninolytic enzyme production assessed as pectinase activity using pectin as substrate at 1 mM measured at 28 degC after 4 days,Other,23731643.0,
1019,1107735,1,1,,103207410,445858,Inactive,,,,,Decrease in Neofusicoccum ribis ligninolytic enzyme production assessed as pectinase activity using pectin as substrate measured at 28 degC after 4 days,Other,23731643.0,
1020,1107736,1,1,,103207410,445858,Unspecified,,,,,Decrease in Lasiodiplodia theobromae ligninolytic enzyme production assessed as pectinase activity using pectin as substrate at 25 mM measured at 28 degC after 4 days,Other,23731643.0,
1021,1107739,1,1,,103207410,445858,Unspecified,,,,,Decrease in Botryosphaeria dothidea ligninolytic enzyme production assessed as laccase activity using ABTS as substrate at 5 mM measured at 28 degC after 4 days,Other,23731643.0,
1022,1107740,1,1,,103207410,445858,Active,,,,,Decrease in Botryosphaeria dothidea ligninolytic enzyme production assessed as laccase activity using ABTS as substrate measured at 28 degC after 4 days,Other,23731643.0,
1023,1107741,1,1,,103207410,445858,Unspecified,,,,,Decrease in Lasiodiplodia theobromae ligninolytic enzyme production assessed as laccase activity using ABTS as substrate at 1 mM measured at 28 degC after 4 days,Other,23731643.0,
1024,1107742,1,1,,103207410,445858,Unspecified,,,,,Decrease in Neofusicoccum ribis ligninolytic enzyme production assessed as laccase activity using ABTS as substrate at 1 mM measured at 28 degC after 4 days,Other,23731643.0,
1025,1107745,1,1,,103207410,445858,Unspecified,,,,,Decrease in Lasiodiplodia theobromae mycelium biomass production measured at 28 degC after 4 days by gravimetric analysis,Other,23731643.0,
1026,1107746,1,1,,103207410,445858,Unspecified,,,,,Decrease in Diplodia seriata (Schwein.) Shoemaker mycelium biomass production measured at 28 degC after 4 days by gravimetric analysis,Other,23731643.0,
1027,1107751,1,1,,103207410,445858,Active,,,,,Inhibition of Diplodia seriata (Schwein.) Shoemaker mycelium growth at 15 mM measured at 28 degC after 4 days,Other,23731643.0,
1028,1107754,1,1,,103207410,445858,Unspecified,,,,,Inhibition of Neofusicoccum ribis mycelium growth at 25 mM measured at 28 degC after 4 days,Other,23731643.0,
1029,1107757,1,1,,103207410,445858,Unspecified,,,,,Inhibition of Lasiodiplodia theobromae mycelium growth at 25 mM measured at 28 degC after 4 days,Other,23731643.0,
1030,1107760,1,1,,103207410,445858,Unspecified,,,,,Inhibition of Lasiodiplodia theobromae mycelium growth measured at 28 degC after 4 days,Other,23731643.0,
1031,1107761,1,1,,103207410,445858,Unspecified,,,,,Inhibition of Neofusicoccum ribis mycelium growth measured at 28 degC after 4 days,Other,23731643.0,
1032,1107762,1,1,,103207410,445858,Unspecified,,,,,Inhibition of Diplodia seriata (Schwein.) Shoemaker mycelium growth measured at 28 degC after 4 days,Other,23731643.0,
1033,1107763,1,1,,103207410,445858,Unspecified,,,,,Inhibition of Botryosphaeria dothidea mycelium growth measured at 28 degC after 4 days,Other,23731643.0,
1034,1116046,1,2,,103207410,445858,Unspecified,,,,,Antimicrobial activity against Streptococcus pyogenes 10535 assessed as growth inhibition after 24 hr by serial dilution method,Other,,
1035,1116047,1,2,,103207410,445858,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus 209 assessed as growth inhibition after 24 hr by serial dilution method,Other,,
1036,1116048,1,2,,103207410,445858,Active,,,,,Inhibition of autoxidation of pure triacylglycerols of sunflower oil at 1 mM by iodometric analysis,Other,,
1037,1116049,1,3,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity at 3.6 mM after 20 min,Other,,
1038,1116050,1,3,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity at 3.6 mM after 10 min,Other,,
1039,1116051,1,3,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity at 1.8 mM after 20 min,Other,,
1040,1116052,1,3,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity at 0.9 mM after 20 min,Other,,
1041,1116053,1,3,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity at 1.8 mM after 10 min,Other,,
1042,1116054,1,3,,103207410,445858,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity at 0.9 mM after 10 min,Other,,
1043,1159524,1,1,,26748470,445858,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1044,1159524,1,1,,47193700,445858,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1045,1159550,3,1,,252401651,445858,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
1046,1159580,2,1,,268735806,445858,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1047,1159606,1,1,,57264356,445858,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
1048,1159607,2,1,,312995440,445858,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1049,1191124,1,2,,103207410,445858,Unspecified,,,,,Inhibition of Pseudomonas aeruginosa recombinant PqsD expressed in Escherichia coli BL21 (lambdaDE3) using ACoA/beta-ketodecanoic acid as substrate at 50 uM after 10 mins,Other,25437621.0,
1050,1191128,1,1,,103207410,445858,Inconclusive,,,,,Inhibition of Pseudomonas aeruginosa PA14 PqsH transposon mutant assessed as extracellular level of HHQ at 250 uM after 16 hrs,Other,25437621.0,
1051,1192870,1,1,,103207410,445858,Unspecified,,,100.0,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay,Confirmatory,25666824.0,
1052,1198409,1,1,,103207410,445858,Unspecified,,,,,Anticandidal activity against Candida albicans ATCC 90028 incubated at 37 degC for 24 hrs by broth dilution method,Other,25686593.0,
1053,1198410,1,1,,103207410,445858,Unspecified,,,,,Fungicidal activity against Candida albicans ATCC 90028 incubated at 37 degC for 48 hrs by broth dilution method,Other,25686593.0,
1054,1198411,1,1,,103207410,445858,Unspecified,,,,,Anticandidal activity against Candida glabrata ATCC 90030 incubated at 37 degC for 24 hrs by broth dilution method,Other,25686593.0,
1055,1198412,1,1,,103207410,445858,Unspecified,,,,,Fungicidal activity against Candida glabrata ATCC 90030 incubated at 37 degC for 48 hrs by broth dilution method,Other,25686593.0,
1056,1198413,1,1,,103207410,445858,Unspecified,,,,,Anticandidal activity against Candida tropicalis ATCC 750 incubated at 37 degC for 24 hrs by broth dilution method,Other,25686593.0,
1057,1198414,1,1,,103207410,445858,Unspecified,,,,,Fungicidal activity against Candida tropicalis ATCC 750 incubated at 37 degC for 48 hrs by broth dilution method,Other,25686593.0,
1058,1198415,1,1,,103207410,445858,Inconclusive,,,,,Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red assay,Other,25686593.0,
1059,1223489,1,1,,103207410,445858,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake flask method",Other,22096083.0,
1060,1223493,1,1,,103207410,445858,Unspecified,,,,,Apparent permeability from apical to basolateral side in human Caco2 cells at 500 uM at pH 7.4 after 1 hr by HPLC-DAD analysis,Other,22096083.0,
1061,1223494,1,1,,103207410,445858,Unspecified,,,,,Apparent permeability from basolateral to apical side in human Caco2 cells at 500 uM at pH 7.4 after 1 hr by HPLC-DAD analysis,Other,22096083.0,
1062,1223495,1,1,,103207410,445858,Unspecified,,,,,Efflux ratio of apparent permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells at 500 uM after 1 hr by HPLC-DAD analysis,Other,22096083.0,
1063,1223496,1,1,,103207410,445858,Unspecified,,,,,Apparent permeability across human Caco2 cells with high TEER resistance at 500 uM after 1 hr by HPLC-DAD analysis,Other,22096083.0,
1064,1223497,1,1,,103207410,445858,Unspecified,,,,,Apparent permeability across human Caco2 cells with low TEER resistance at 500 uM after 1 hr by HPLC-DAD analysis,Other,22096083.0,
1065,1224865,1,2,,57264356,445858,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
1066,1233172,1,1,,103207410,445858,Inactive,,,,,Antimicrobial activity against Staphylococcus aureus after 5 to 12 hrs by micro broth dilution assay,Other,25981689.0,
1067,1233173,1,1,,103207410,445858,Inactive,,,,,Antimicrobial activity against Escherichia coli after 5 to 12 hrs by micro broth dilution assay,Other,25981689.0,
1068,1248399,1,1,,103207410,445858,Unspecified,,,5000.0,IC50,Inhibition of alpha-amylase (unknown origin) relative to control,Confirmatory,26395057.0,
1069,1254173,1,1,,103207410,445858,Active,5915866.0,771.0,9.78,Ki,Inhibition of human catalytic domain of carbonic anhydrase 12 preincubated for 15 mins by stopped-flow CO2 hydration assay,Confirmatory,26498394.0,
1070,1254174,1,1,,103207410,445858,Active,30580372.0,71934.0,12.2,Ki,Inhibition of mouse carbonic anhydrase 13 preincubated for 15 mins by stopped-flow CO2 hydration assay,Confirmatory,26498394.0,
1071,1254175,1,1,,103207410,445858,Active,8928036.0,23632.0,9.43,Ki,Inhibition of human carbonic anhydrase 14 preincubated for 15 mins by stopped-flow CO2 hydration assay,Confirmatory,26498394.0,
1072,1259309,1,1,,124812733,445858,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
1073,1259310,1,1,,333473197,445858,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1074,1259311,1,1,,124812733,445858,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
1075,1259313,1,1,,47193700,445858,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
1076,1259318,1,1,,57264356,445858,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
1077,1259389,1,1,,124636706,445858,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
1078,1259407,1,1,,363901206,445858,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1079,1259409,1,1,,363901206,445858,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
1080,1259409,1,1,,363905077,445858,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
1081,1259409,1,1,,363905525,445858,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
